Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6102575 | 0.91 | HTR1A (0.39) | KDM4EALDH1A1POLBDRD2 | |
| SCHEMBL6103020 | 0.90 | KDM4E (0.45) | KDM4EALDH1A1DRD4DRD3 | |
| SCHEMBL5652466 | 0.88 | KDM4E (0.48) | KDM4EALDH1A1TDP1POLBLMNA | |
| SCHEMBL5713966 | 0.86 | MGLL (0.41) | KDM4EALDH1A1POLBDRD2DRD4 | |
| SCHEMBL5714582 | 0.86 | KDM4E (0.43) | KDM4EALDH1A1TDP1POLBLMNA | |
| SCHEMBL5713903 | 0.85 | ALDH1A1 (0.51) | KDM4EALDH1A1POLBLMNAGFER | |
| SCHEMBL5714957 | 0.84 | KDM4E (0.37) | KDM4EALDH1A1LMNAGFERDRD2 | |
| SCHEMBL5714634 | 0.82 | KDM4E (0.47) | KDM4EALDH1A1TDP1POLBLMNA | |
| SCHEMBL5714886 | 0.81 | EGLN1 (0.40) | KDM4EALDH1A1LMNA | |
| SCHEMBL5715300 | 0.81 | HTR1A (0.40) | KDM4EALDH1A1POLBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | LIPE, PNLIP, LPL | KDM4E 1090/4885ALDH1A1 1504/4885TDP1 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.